Remove Bioinformatics Remove Genetic Engineering Remove Licensing Remove Production
article thumbnail

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRatĀ® and OmniFlicĀ®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.

article thumbnail

United Therapeutics Corporation Reports Third Quarter 2020 Financial Results

The Pharma Data

“As our core business continues to perform well, we have a solid footing to enter 2021 with several key product launches including the potential INCREASE product label expansion for Tyvaso, the Remunity Pump for Remodulin, and the Implantable System for Remodulin,” said Martine Rothblatt , Ph.D., SILVER SPRING, Md.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Thereafter, there will be two presentations, which are: Jan Terje Andersen, PhD, Professor, Department of Pharmacology, University of Oslo; Research Group Leader, Department of Immunology, Oslo University Hospital, on: ā€˜Biology-based engineering of versatile antibody and albumin technologiesā€™.